Most cell and stem cell therapies fail beyond blood cancers because delivery cannot preserve function in solid organs. ClexBio’s biological platform enables safe, durable solid tissue replacement, unlocking regenerative therapies for liver failure, type 1 diabetes, and heart disease.
- https://www.clexbio.com/
- Send an email
- Armend Hati
Some insights
We enable stem cell therapies to work in solid organs by solving delivery. Our biological platform supports safe, durable tissue replacement, aiming to treat liver failure, type 1 diabetes, and heart disease where transplants are limited and patients have no options.
We challenge the status quo of cell infusion and synthetic devices with a biology-first platform. In a field full of promises, we focus on function, safety, and scalability, building real tissue therapies with global impact potential.
Companies that built category-defining platforms, such as Genentech, Regeneron, and Moderna. In stem cell therapy, pioneers like BlueRock and Vertex showed that bold science, strong IP, and smart partnerships can reshape medicine.
Our strengths are stem cell biology, bioengineering, GMP translation, and pharma deal experience. Next, we aim to add deeper clinical development, regulatory leadership, and scaled manufacturing expertise.
They would say I try to help build new organs from cells so doctors can save people whose livers or hearts are failing.
By fostering early clinical partnerships, facilitating access to GMP infrastructure, and strengthening links between biotech, pharma, and leading hospitals to accelerate translation of advanced therapies.
Pharma partners in stem cell therapy, CDMOs for GMP scale-up, transplant and hepatology leaders, regulatory experts, and investors experienced in advanced therapies and platform biotech.
